|
Thrombolytic Science International (TSI) is a private biopharmaceutical company beginning Phase I clinical trials of TS01, a new-generation therapy to treat acute strokes and heart attacks.〔Hay, Timothy. (12 January 2012). "With $7.5M, TSI Aims To Succeed Where Bat Spit, Snake Venom Failed." Dow Jones VentureWire.〕 Tissue plasminogen activator (tPA) has remained the only clot-dissolving, thrombolytic drug available for clinical use in patients with ischemic stroke since its approval in 1996.〔Haas, Michael J.. (22 March 2012). "Monkeys bridge the stroke gap." SciBX.〕 Only about 5% of stroke patients are treated with tPA because of its short treatment time-window, suboptimal efficacy, and risk of intra-cranial hemorrhage.〔Rhodes, Jennifer. (6 February 2012). "Specifying Stroke." BioCentury.〕 TS01 is a clot-dissolving treatment consisting of a mutated form of the first-generation thrombolytic, pro-urokinase (pro-UK) preceded by a bolus of plasma complement 1 esterase inhibitor (C1-inhibitor).〔Haas, Michael J.. (22 March 2012). "Monkeys bridge the stroke gap." SciBX.〕 TS01 targets only the occlusive (bad) clots that lead to stroke, a fact which the company expects will significantly reduce the risk of bleeding. Like its parent molecule pro-UK, TS01 is also expected to show a longer treatment time-window than tPA. These attributes will allow many more patients to be treated with this potentially life-saving treatment.〔Rhodes, Jennifer. (6 February 2012). "Specifying Stroke." BioCentury.〕 == Peer-Reviewed Articles == * 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Thrombolytic Science International」の詳細全文を読む スポンサード リンク
|